Corvus Launches Phase 1B Trial of Soquelitinib in Hidradenitis Suppurativa
CRVS sits 83% above its 52-week low of $6.39.
Summary
Corvus Pharmaceuticals has initiated a Phase 1B clinical trial of soquelitinib for patients with hidradenitis suppurativa, a chronic inflammatory skin condition. The primary endpoint is safety and tolerability, with key efficacy measured by HiSCR 50/75 at Week 12. This expands soquelitinib's development beyond oncology into immunology, potentially broadening the drug's market opportunity. The company's cash position of $236.7 million as of Q1 2026 provides runway for this trial. No prior news in the timeline covers this specific trial initiation, making it a fresh development.
At the time of this announcement, CRVS was trading at $11.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $969.1M. The 52-week trading range was $6.39 to $26.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.